Going head-to-head with Merck on I/O, Genentech vets raise fresh round and enter clinic

news
Written By Guest User
Guest User
Previous

Immune-Onc ratchets up a series B1 and B2 for $73M
Next

Immune-Onc Building Broad Pipeline of Myeloid Checkpoint Inhibitors